Management of Cancer-Treatment–Induced Bone Loss in Postmenopausal Women Undergoing Adjuvant Breast Cancer Therapy: A Z-FAST Update
- 1 April 2006
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 33, 13-17
- https://doi.org/10.1053/j.seminoncol.2006.03.022
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Effects of skeletal complications on total medical care costs in patients with bone metastases of solid tumorsJournal of Clinical Oncology, 2005
- P103 Zoledronic acid inhibits cancer treatment-induced bone loss in premenopausal patients with breast cancer who are receiving adjuvant endocrine treatmentThe Breast, 2005
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004Journal of Clinical Oncology, 2005
- Skeletal health in postmenopausal survivors of early breast cancerInternational Journal of Cancer, 2005
- Long-term implications of bone loss in breast cancerThe Breast, 2004
- Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapySeminars in Oncology, 2004
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancerCancer, 2003
- Osteoporosis Due to Cancer Treatment: Pathogenesis and ManagementJournal of Clinical Oncology, 2000